glp 1 and the brain Interaction between GLP-1 signaling neural reward pathways. GLP-1 Frontiers | Revisiting food addiction

The FDA states that exenatide, the first GLP-1 receptor agonist, is being phased out as of January 2025 due to a GLP-1 scarcity

& Choudhury, Y

Research using data from U-M Healths primary care clinics shows that patients lose more weight, and sustain that loss, if they receive care guided by a provider trained in obesity medicine, and wraparound services, in addition to a prescription for a weight management medication

Taken together, iron oxide, gold, and hybrid nano-architectures offer complementary strengths, combining high-resolution MR tracking, photothermal actuation, and pharmacokinetic tuning

Available from: Available online at: (cited May 5, 2024)

The ER formulation of exenatide achieves sustained drug concentrations in plasma over time (Figure 2B)